Anthem Selects Gilead as Primary Supplier of Hepatitis C Drugs

Health insurer Anthem Inc has reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.

Gilead

Sciences

Health insurer Anthem Inc on Thursday said it reached a deal under which Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.

Anthem said the deal effectively lowers its hepatitis C treatment costs.

Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the largest US pharmacy benefit manager, subsequently chose AbbVie's drug as the exclusive option for patients in its largest commercial plan, covering 25 million people.

However, CVS has also chosen to go with Harvoni.

Read more: http://reut.rs/1KqygvC

Source: Reuters